Teva’s Copaxone patent invalidated for second time

22-06-2015

Teva’s Copaxone patent invalidated for second time

Photo: Courtesy of Teva

A US appeals court has for the second time invalidated a patent covering pharmaceutical company Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).


Teva, Mylan, Copaxone, patent, US Court of Appeals for the Federal Circuit, glatiramer acetate, Sandoz

LSIPR